Protein kinase CK2: a newcomer in the ‘druggable kinome’
- 25 October 2006
- journal article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 34 (6) , 1303-1306
Abstract
The acronym CK2 (derived from the misnomer ‘casein kinase’ 2) denotes one of the most pleiotropic members of the eukaryotic protein kinase superfamily, characterized by an acidic consensus sequence in which a carboxylic acid (or pre-phosphorylated) side chain at position n+3 relative to the target serine/threonine residue plays a crucial role. The latest repertoire of CK2 substrates includes approx. 300 proteins, but the analysis of available phosphopeptide databases from different sources suggests that CK2 alone may be responsible for the generation of a much larger proportion (10–20%) of the eukaryotic phosphoproteome. Although for the time being CK2 is not included among protein kinases whose inhibitors are in clinical practice or in advanced clinical trials, evidence is accumulating that elevated CK2 constitutive activity co-operates to induce a number of pathological conditions, including cancer, infectious diseases, neurodegeneration and cardiovascular pathologies. The development and usage of cell-permeant, selective inhibitors discloses a scenario whereby CK2 plays a global anti-apoptotic role, which under special circumstances may lead to untimely and pathogenic cell survival.Keywords
This publication has 22 references indexed in Scilit:
- Histone deacetylase inhibitors prevent exocytosis of interleukin-1β-containing secretory lysosomes: role of microtubulesBlood, 2006
- Multiple myeloma cell survival relies on high activity of protein kinase CK2Blood, 2006
- Comprehensive Identification of Phosphorylation Sites in Postsynaptic Density PreparationsMolecular & Cellular Proteomics, 2006
- Protein kinase CK2 phosphorylates and upregulates Akt/PKBCell Death & Differentiation, 2005
- Phosphoproteomic Analysis of the Developing Mouse BrainMolecular & Cellular Proteomics, 2004
- Inhibition of Protein Kinase CK2 by Condensed Polyphenolic Derivatives. An in Vitro and in Vivo StudyBiochemistry, 2004
- One‐thousand‐and‐one substrates of protein kinase CK2?The FASEB Journal, 2003
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)FEBS Letters, 2001